

“CONOCE AL DETALLE EL CLÚSTER SALUD DE HORIZONTE EUROPA”

Juan Riese
Oficina de Proyectos
15/05/24



IACS_in_Europe

Ciclo de charlas: “Horizonte Europa a tu alcance”

- Financiación de la I+D en Horizonte Europa: ¿cómo aprovechar nuevas oportunidades de participación para su segunda parte 2025-2027?
- **Conoce al detalle el Clúster de Salud de Horizonte Europa.**
- Oportunidades de participación en la Misión Cáncer de Horizonte Europa (13 de junio).
- Horizonte Europa: entender los aspectos legales y financieros del programa para participar mejor.
- Conociendo en detalle el formulario de solicitud (“template”) de las propuestas Horizonte Europa.
- Inclusión de la perspectiva de género en la investigación científica en salud.
- Cómo elaborar el Data Management Plan de un proyecto europeo.
- Estrategias y habilidades para aprender a divulgar ciencia a la sociedad.
- Novedades en el formulario sobre ética en Horizonte Europa.
- Innovación Social en proyectos de investigación.
- Cómo diseñar un plan de comunicación de un proyecto en Horizonte Europa.



GOBIERNO
DE ESPAÑA

MINISTERIO
DE CIENCIA, INNOVACIÓN
Y UNIVERSIDADES



Esta actividad es parte de la actuación GPE2023-001276-P (Convocatoria “Preparación y gestión de proyectos europeos y atracción de talento internacional 2023”), financiada por MICIU/AEI/10.13039/501100011033.

Recordando la sesión 1 del 18.04.2024

Agenda

- Programa Marco
- Lógica de definición de las convocatorias europeas
- Plan Estratégico Horizonte Europa
- Programa Marco Horizonte Europa
 - Estructura
 - Impact-driven programme
 - Misiones
 - Partenariados
- Plan Estratégico 2025-2027

Sesión 2 - 15.05.2024

Agenda

1. Estructura básica de Horizonte Europa
2. Descripción del Programa de Trabajo del Clúster Salud.
3. Análisis de los apartados de un topic
4. Reglas generales de participación
5. ¿Cómo puedo solicitar financiación?

“Do you want to sell sugar water for the rest of your life, or do you want to change the world?”




Sesión 2 - 15.05.2024

Agenda

1. Estructura básica de Horizonte Europa
2. Descripción del Programa de Trabajo del Clúster Salud.
3. Análisis de los apartados de un topic
4. Reglas generales de participación
5. ¿Cómo puedo solicitar financiación?

Estructura de Horizonte Europa



* The European Institute of Innovation & Technology (EIT) is not part of the Specific Programme





HORIZON EUROPE

EURATOM



* The European Institute of Innovation & Technology (EIT) is not part of the Specific Programme



Pilar 1

CIENCIA EXCELENTE:

reforzar y ampliar la excelencia de la base científica de la Unión

Consejo Europeo de Investigación

- Investigación de frontera realizada por los mejores investigadores y sus equipos.

Propuesta de la Comisión:
14 861 millones EUR

Acciones Marie Skłodowska-Curie

- Proporcionar a los investigadores nuevos conocimientos y capacidades a través de la movilidad y la formación.

Propuesta de la Comisión:
6 288 millones EUR

Infraestructuras de investigación

- Infraestructuras de investigación de primera categoría mundial, integradas e interrelacionadas.

Propuesta de la Comisión:
2 149 millones EUR

Guías rápidas de Proyectos Europeos





HORIZON EUROPE

EURATOM




* The European Institute of Innovation & Technology (EIT) is not part of the Specific Programme





HORIZON EUROPE

EURATOM



* The European Institute of Innovation & Technology (EIT) is not part of the Specific Programme



Pilar 3

EUROPA INNOVADORA:

estimular las innovaciones de vanguardia y creadoras de mercados y los ecosistemas que propician la innovación

Consejo Europeo de Innovación

- Apoyo a las innovaciones de vanguardia y con potencial de creación de mercados.

Ecosistemas europeos de innovación

- Conexión entre agentes regionales y nacionales de innovación.

Instituto Europeo de Innovación y Tecnología (EIT)

- Reunión de los agentes principales (investigación, educación y empresas) en torno a un objetivo común para fomentar la innovación.

8.752 millones EUR para EIC
448 millones EUR para ecosistemas

2.686 millones EUR



Sesión 2 - 15.05.2024

Agenda

1. Estructura básica de Horizonte Europa
2. Descripción del Programa de Trabajo del Clúster Salud.
3. Análisis de los apartados de un topic
4. Reglas generales de participación
5. ¿Cómo puedo solicitar financiación?



EN

Horizon Europe
Work Programme 2023-2025

4. Health

(European Commission Decision C(2024) 2371 of 17 April 2024)

Table of contents

Introduction	7
Destination 1 – Staying healthy in a rapidly changing society.....	13
Call - Staying Healthy (Single stage - 2023).....	16
Conditions for the Call	16
HORIZON-HLTH-2023-STAYHLTH-01-01: The Silver Deal - Person-centred health and care in European regions	17
Call - Staying Healthy (Two stage - 2024).....	20
Conditions for the Call.....	20
HORIZON-HLTH-2024-STAYHLTH-01-02-two-stage: Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society	22
HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage: Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources.....	25
Destination 2. Living and working in a health-promoting environment	31
Call - Environment and health (Single stage - 2023).....	34
Conditions for the Call	34
HORIZON-HLTH-2023-ENVHLTH-02-01: Planetary health: understanding the links between environmental degradation and health impacts.....	35
HORIZON-HLTH-2023-ENVHLTH-02-02: Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)	39
HORIZON-HLTH-2023-ENVHLTH-02-03: Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties .	44
HORIZON-HLTH-2023-ENVHLTH-02-04: Global coordination of exposome research..	48
Call - Environment and health (Two stage - 2024)	51
Conditions for the Call	51
HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage: The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution	53
Destination 3. Tackling diseases and reducing disease burden	59
Call - Tackling diseases (Single stage - 2023).....	64
Conditions for the Call	64
HORIZON-HLTH-2023-DISEASE-03-01: Novel approaches for palliative and end-of-life care for non-cancer patients	65

La introducción al texto

The work programme 2023-2024 of cluster 1 'Health' is **directed towards two Key Strategic Orientations (KSOs)** for research and innovation **set by Horizon Europe's strategic plan 2021-2024**, notably to creating a more resilient, inclusive and democratic European society (KSO-D) and promoting an open strategic autonomy by leading the development of key digital, enabling and emerging technologies, sectors and value chains (KSO-A).

It aims to complete the targets set out in the Strategic Plan 2021-2024, mainly along the **four impact areas**:

1. Good health and high-quality accessible health care;
2. A resilient EU prepared for emerging threats;
3. High quality digital services for all; and
4. A competitive and secure data-economy

Impactos = “Destinations” (Destinos) (I)

More specifically, cluster 1 strives to contribute to **six expected impacts** as **set out by the Strategic Plan**, which are the following six destinations of this work programme:

Destination 1 - Staying healthy in a rapidly changing society: Citizens of all ages stay healthy and independent in a rapidly changing society thanks to healthier lifestyles and behaviours, healthier diets, healthier environments, improved evidence-based health policies, and more effective solutions for health promotion and disease prevention.

Destination 2 - Living and working in a health-promoting environment: Living and working environments are health-promoting and sustainable thanks to better understanding of environmental, occupational, social and economic determinants of health.

Destination 3 - Tackling diseases and reducing disease burden: Health care providers are able to better tackle and manage diseases (infectious diseases, including poverty-related and neglected diseases, non-communicable and rare diseases) and reduce the disease burden on patients effectively thanks to better understanding and treatment of diseases, more effective and innovative health technologies, better ability and preparedness to manage epidemic outbreaks and improved patient safety.

Impactos = “Destinations” (Destinos) (I)

Six expected impacts as set out by the Strategic Plan



Destination 1 Staying healthy in a rapidly changing society

Thanks to healthier lifestyles and behaviours, healthier diets, healthier environments, improved evidence-based health policies, and more effective solutions for health promotion and disease prevention



Destination 2 Living and working in a health-promoting environment

Living and working environments are health-promoting and sustainable thanks to better understanding of environmental, occupational, social and economic determinants of health.



Destination 3 Tackling diseases and reducing disease burden

Health care providers are able to better tackle and manage diseases (infectious diseases, including poverty-related and neglected diseases, non-communicable and rare diseases) and reduce the disease burden on patients effectively thanks to better understanding and treatment of diseases, more effective and innovative health technologies, better ability and preparedness to manage epidemic outbreaks and improved patient safety.

Impactos = “Destinations” (Destinos) (II)

Destination 4 - Ensuring access to innovative, sustainable and high-quality health care:

Health care systems provide equal access to innovative, sustainable and high-quality health care thanks to the development and uptake of safe, cost-effective and people-centred solutions, with a focus on population health, health systems resilience, as well as improved evidence-based health policies.

Destination 5 - Unlocking the full potential of new tools, technologies and digital solutions for a healthy society:

Health technologies, new tools and digital solutions are applied effectively thanks to their inclusive, secure and ethical development, delivery, integration and deployment in health policies and health care systems.

Destination 6 - Maintaining an innovative, sustainable and globally competitive health-related industry:

EU health industry is innovative, sustainable and globally competitive thanks to improved up-take of breakthrough technologies and innovations, which makes the EU with its Member States more resilient and less dependent from imports with regard to the access to and supply of critical health technologies.

Impactos = “Destinations” (Destinos) (II)



Destination 4 **Ensuring access to innovative, sustainable and high-quality health care:**

Health care systems provide equal access to innovative, sustainable and high-quality health care thanks to the development and uptake of safe, cost-effective and people-centred solutions, with a focus on population health, health systems resilience, as well as improved evidence-based health policies.



Destination 5 **Unlocking the full potential of new tools, technologies and digital solutions for a healthy society:**

Health technologies, new tools and digital solutions are applied effectively thanks to their inclusive, secure and ethical development, delivery, integration and deployment in health policies and health care systems.



Destination 6 **Maintaining an innovative, sustainable and globally competitive health-related industry:**

EU health industry is innovative, sustainable and globally competitive thanks to improved up-take of breakthrough technologies and innovations, which makes the EU with its Member States more resilient and less dependent from imports with regard to the access to and supply of critical health technologies.

Table of contents

Introduction	7
Destination 1 – Staying healthy in a rapidly changing society	13
Call - Staying Healthy (Single stage - 2023)	16
Conditions for the Call	16
HORIZON-HLTH-2023-STAYHLTH-01-01: The Silver Deal - Person-centred health and care in European regions	17
Call - Staying Healthy (Two stage - 2024)	20
Conditions for the Call	20
HORIZON-HLTH-2024-STAYHLTH-01-02-two-stage: Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society	22
HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage: Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources.....	25
Destination 2. Living and working in a health-promoting environment	31
Call - Environment and health (Single stage - 2023)	34
Conditions for the Call	34
HORIZON-HLTH-2023-ENVHLTH-02-01: Planetary health: understanding the links between environmental degradation and health impacts.....	35
HORIZON-HLTH-2023-ENVHLTH-02-02: Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)	39
HORIZON-HLTH-2023-ENVHLTH-02-03: Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties .	44
HORIZON-HLTH-2023-ENVHLTH-02-04: Global coordination of exposome research..	48
Call - Environment and health (Two stage - 2024)	51
Conditions for the Call	51
HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage: The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution	53
Destination 3. Tackling diseases and reducing disease burden	59
Call - Tackling diseases (Single stage - 2023)	64
Conditions for the Call	64
HORIZON-HLTH-2023-DISEASE-03-01: Novel approaches for palliative and end-of-life care for non-cancer patients	65

El ejemplo del “Destino 1”

Los impactos específicos esperados en el Destino 1

Impactos concretos esperados en el Destino 1: *Staying healthy in a rapidly changing society (I)*

Expected impacts:

Proposals for topics under this destination should set out a credible pathway to contributing to staying healthy in a rapidly changing society, and more specifically to one or several of the following impacts:

- **Citizens adopt healthier lifestyles and behaviours**, make healthier choices and maintain longer a healthy, independent and active life with a reduced disease burden, including at old ages or in other vulnerable stages of life.
- **Citizens are able and empowered to manage better their own physical and mental health and well-being**, monitor their health, and interact with their doctors and health care providers.
- **Children and adolescents are empowered to better monitor and manage their physical, social and mental health** with a view to lifelong healthy lifestyles.

Impactos concretos esperados en el Destino 1.

Staying healthy in a rapidly changing society (II)

- **Society benefits from reduced economic and health burden from avoidable sickness, disease and premature death.** Efficiency is increased by targeting scarce resources in appropriate, cost-effective ways, to areas of high social return, contributing to an improvement and optimisation of health and well-being of citizens and reduction of health inequalities.
- **Citizens' trust in knowledge-based health interventions and in guidance from health authorities is strengthened,** including through improved health literacy, resulting in increased engagement in and adherence to effective strategies for health promotion, disease prevention and treatment, while digital literacy inequalities are minimised.
- **Health policies and actions for health promotion and disease prevention are knowledge-based, people-centred, personalised** and thus targeted and tailored to citizens' needs, and designed to reduce health inequalities.

Conditions for the Call

Indicative budget(s)³⁵

Topics	Type of Action	Budgets (EUR million)	Expected EU contribution per project (EUR million) ³⁶	Indicative number of projects expected to be funded
		2024		
Opening: 30 Mar 2023				
Deadline(s): 19 Sep 2023 (First Stage), 11 Apr 2024 (Second Stage)				
HORIZON-HLTH-2024-STAYHLTH-01-02-two-stage	RIA	30.00	8.00 to 10.00	3
HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage	RIA	50.00	8.00 to 12.00	5
Overall indicative budget		80.00		

General conditions relating to this call	
<i>Admissibility conditions</i>	The conditions are described in General Annex A.
<i>Eligibility conditions</i>	The conditions are described in General Annex B.
<i>Financial and operational capacity and exclusion</i>	The criteria are described in General Annex C.
<i>Award criteria</i>	The criteria are described in General Annex D.
<i>Documents</i>	The documents are described in General Annex E.
<i>Procedure</i>	The procedure is described in General Annex F.
<i>Legal and financial set-up of the Grant</i>	The rules are described in General Annex G.

³⁵ The Director-General responsible for the call may decide to open the call up to one month prior to or after the envisaged date(s) of opening.
The Director-General responsible may delay the deadline(s) by up to two months.
All deadlines are at 17.00.00 Brussels local time.

The budget amounts are subject to the availability of the appropriations provided for in the general budget of the Union for years 2023, 2024 and 2025.

³⁶ Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

Tabla resumen de las características del “Destino” (I)

Sesión 2 - 15.05.2024

Agenda

1. Estructura básica de Horizonte Europa
2. Descripción del Programa de Trabajo del Clúster Salud.
3. Análisis de los apartados de un topic
4. Reglas generales de participación
5. ¿Cómo puedo solicitar financiación?

Apartados del “topic”

- Código de designación y título del topic
- Tabla de condiciones específicas
- “Expected outcomes”
- “Scope”
- Notas al pie de página

Título y cuadro de condiciones del topic (I)

HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage: Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources

Specific conditions	
<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of between EUR 8.00 and 12.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 50.00 million.
<i>Type of Action</i>	Research and Innovation Actions
<i>Admissibility conditions</i>	<p>The conditions are described in General Annex A. The following exceptions apply:</p> <p>Applicants submitting a proposal under the blind evaluation pilot (see General Annex F) must not disclose their organisation names, acronyms, logos, nor names of personnel in Part B of their first stage application (see General Annex E).</p>
<i>Eligibility conditions</i>	<p>The conditions are described in General Annex B. The following exceptions apply:</p> <p>In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.</p> <p>If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).</p>

Participación de los EEUU



Título y cuadro de condiciones del topic (II)

<i>Award criteria</i>	<p>The criteria are described in General Annex D. The following exceptions apply:</p> <p>For the second stage, the thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.</p>
<i>Procedure</i>	<p>The procedure is described in General Annex F. The following exceptions apply:</p> <p>This topic is part of the blind evaluation pilot under which first stage proposals will be evaluated blindly.</p>
<i>Legal and financial set-up of the Grant Agreements</i>	<p>The rules are described in General Annex G. The following exceptions apply:</p> <p>Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025). ⁴².</p>

⁴² This [decision](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision-he-en.pdf) is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under 'Simplified costs decisions' or through this link: <https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision-he-en.pdf>

Expected Outcome: This topic aims at supporting activities that are **enabling or contributing to one or several impacts of destination 1** “Staying healthy in a rapidly changing society”. To that end, proposals under this topic should aim at delivering results that are directed at, tailored towards and **contributing to several of the following expected outcomes**:

- **Citizens have access to and use effective personalised prevention schemes and health counselling** (including through digital means) that take into account their individual characteristics and situation. Individuals can be assigned to particular groups based on their characteristics, and receive advice adequate to that group. Stratification of a population into groups showing similar traits allows for effective personalised disease prevention.
- **Health professionals use effective, tried and tested tools to facilitate their work when advising both patients and healthy individuals.** Public health programme owners gain insight into the specificities and characteristics of disease clusters within the population through stratification. This can then be used to facilitate the identification of population groups with elevated risk of developing certain diseases and improve the programmes, update them and design effective strategies for optimal solutions and interventions.
- **National and regional programmes make better use of funds, data infrastructure and personnel in health promotion and disease prevention, primary and secondary healthcare.** They can consider the use of new or improved ambitious policy and intervention options, with expected high population-wide impact, for effective health promotion and disease prevention.
- **Companies generate opportunities** for new product and service developments to cater to the needs of the healthcare service and individuals.

Apartado “Expected Outcomes”

Apartado “Scope” (I)

Scope: Non-communicable diseases (NCDs) are responsible for the majority of the disease burden in Europe and are the leading cause of avoidable premature death. The human and financial cost of NCDs is high and expected to grow. Reducing the burden of NCDs requires a holistic approach and tackling health inequalities across the board. Preventing NCDs from developing in the first place will be at the core of successful public health programmes in the future.

Personalised approaches and the development of targeted interventions have led to an impressive progress in several fields of medicine and have been included in many treatments. However, the use of stratification and individualisation in guiding prevention strategies is still not widely in use even though examples of its potential are accumulating. Identifying people at risk of developing a particular disease before the disease starts to manifest itself with symptoms greatly improves treatment options. It is estimated that about two thirds of all NCDs are preventable, many affecting people who are unaware of their disease risks or do not have access to information pertaining to the management of the condition.

Personalised prevention is the assessment of health risks for individuals based on their specific background traits⁴³ to recommend tailored prevention⁴⁴. This can include any evidence-based method⁴⁵. Personalised prevention strategies complement general public health prevention programmes without replacing them, optimising the benefit of both approaches. Personalised prevention is ideally suited to the use of large data sets, computational and omics approaches, with design and use of algorithms, integrating in-depth biological and medical information, machine learning, artificial intelligence (AI) and ‘virtual twin’ technology, taking into account explainable and transparent AI⁴⁶.

The funded projects will work towards reducing the burden of NCDs in line with the ‘Healthier Together’ – EU Non-Communicable Diseases Initiative⁴⁷. This does not limit the scope of projects under this topic to particular diseases as any disease area of interest, co-morbidities and health determinants⁴⁸ can be addressed.

Accordingly, the proposed research is expected to deliver on all of the following points:

- Enable the understanding of areas of unmet need in NCDs prevention, possibly also addressing disease mechanism, management of disease progression and relapse. Providing new approaches for prevention, focussing on the digitally supported personalised dimension, that can be adopted and scaled up.
- Devise new or improved ambitious policy and intervention options, with expected high population-wide impact on the target groups in question. To be proposed and made available for effective health promotion and disease prevention including targeted communication strategies to successfully reach out to the risk groups.
- Design an integrated, holistic approach that includes several of the following aspects: genetic predisposition to NCDs, meta-genomics, epigenomics, the microbiome, metabolomics, sleep disorders, large cohorts, molecular profiling in longitudinal health screening, impact of lack of physical activity, novel predictive biomarker candidates, diets and nutrition, eating habits for designing customised dietary patterns (geographical variation), and the influence of choice environment on personal choices.
- Study the ethical, legal and social aspects as well as health economics of the personalised prevention tools and programmes being developed. Consider optimal health counselling and communication to the patients/citizens. Address legal aspects of balancing the right not to know and the obligation of helping people in danger.

Furthermore, the proposed research is expected to deliver on several of the following points:

-
- 43 (Epi-)genetic, biological, environmental, lifestyle, social, behavioural, etc.
44 Possibly along with digitally supported disease management schemes.
45 For example: medication, diet programmes, early diagnostics, monitoring, lifestyle advice and
46 modification, specific training/exercise, psychosocial interventions, meditation, etc.
47 See: European strategic research agenda in artificial intelligence: [https://www.elise-ai.eu/work/agenda-](https://www.elise-ai.eu/work/agenda-and-programs)
48 [and-programs](https://ec.europa.eu/health/non-communicable-diseases/overview_en)
https://ec.europa.eu/health/non-communicable-diseases/overview_en
Social and economic environment; physical environment; individual characteristics; behaviour.

Apartado “Scope” (II)

Apartado “Scope” (III)

- **Develop and validate effective strategies to prevent NCDs and optimise health and well-being of citizens (including the most vulnerable).** Propose the strategies to policymakers along with mechanisms to monitor their progress. The strategies need to be aligned with relevant national and European health laws and policies.
- **Provide scientific evidence on interactions between the genetic predisposition to multifactorial diseases and environmental factors or environmental triggers.** Propose scientifically supported personalised prevention strategies that ensure how to modify the environmental drivers of behavioural risk factors.
- **Develop new computational tools combining and analysing comprehensive data with different dimensions⁴⁹ to identify risk factors and modifiers.** Creating procedures and algorithms to combine information from different sources (with standardised common data models) to generate risk scores for several diseases and provide health promotion recommendations for the individual as advised by healthcare professionals. Furthermore, develop advanced computational modelling techniques⁵⁰ for predicting disease risk and predisposition (addressed together in an integrative approach) and identifying the optimal solution/intervention for different target groups and individuals.
- **Develop tools and techniques to increase the efficiency and cost- effectiveness of on the one hand interventions,** adjusting their scope, characteristics and resources, and on the other hand healthcare infrastructure and how it promotes and delivers health promotion, disease prevention, and care effectively to the different population groups.
- **Design tools to collect various data to advance health promotion and disease prevention and strategies for providing omics essays** for the general patient with a focus on cost-effectiveness and flexibility.

Apartado “Scope” (IV)

- Determine how to optimise the benefits of physical activity, smart monitoring of physical activity and sedentary behaviour with measurable data, addressing barriers to uptake and implementation of healthy lifestyles in daily life, understanding what promotion methods work and why, behavioural science to understand healthier choice environments. Balancing the ecosystem associated with the economic, social, and health consequences of NCDs. Affordability related consideration should be taken into account to ensure accessibility of new tools and techniques.
- Conduct data mining of real-world data and develop quantifiable and distinguishable indicators from wearables data, taking into account ‘light-weight’ AI means to ensure patient privacy and short reaction times.
- Demonstrate with a practical prototype on a given health challenge: from multimodal data collection to identification of an effective prevention strategy to be tested and validated for one or several NCDs.

⁹ For example, genomic, biomarkers, metagenomics, diet, synthetic data, lifestyle, wearables (physical activity), mental health, gender, age, physical and social environment.

⁰ Computational techniques, e.g., virtual twin; deep, fair and/or federated machine learning; AI and symbolic AI.

Apartado “Scope” (y V)

Where relevant, the projects should contribute to and create synergies with ongoing national, European and international initiatives such as the European Partnership for Personalised Medicine, the ‘Healthier Together’ - EU Non-Communicable Diseases Initiative⁵¹, Europe’s Beating Cancer Plan and the Mission on Cancer, WHO’s 9 targets for NCDs, the EMA ‘Darwin’ network⁵² etc.

This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

Where relevant, activities should build on and expand results of past and ongoing research projects. Selected projects under this topic are expected to participate in joint activities as appropriate, possibly including also related projects from other call topics. This can take the form of project clustering, workshops, joint dissemination activities etc. Applicants should plan a necessary budget to cover this collaboration.

Applicants invited to the second stage and envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.

El Anexo para estudios clínicos (“clinical studies”)

Clinical study **covers clinical studies/trials/investigations/cohorts** and means, for the purpose of this document, **any systematic prospective or retrospective collection and analysis of health data obtained from individual patients or healthy persons in order to address scientific questions related to the understanding, prevention, diagnosis, monitoring or treatment of a disease, mental illness, or physical condition.** It includes but it is not limited to clinical studies as defined by Regulation 536/2014 (on medicinal products), clinical investigation and clinical evaluation as defined by Regulation 2017/745 (on medical devices), performance study and performance evaluation as defined by Regulation 2017/746 (on in vitro diagnostic medical devices).



Sesión 2 - 15.05.2024

Agenda

1. Estructura básica de Horizonte Europa
2. Descripción del Programa de Trabajo del Clúster Salud.
3. Análisis de los apartados de un topic
4. Reglas generales de participación
5. ¿Cómo puedo solicitar financiación?


Anexos A-H

Anexo A - Admisibilidad

- ✓ Plazo de entrega (deadline)
- ✓ Vía única telemática
- ✓ Completar todos los apartados
- ✓ Solicitudes elegibles, accesibles e imprimibles
- ✓ Requisito absoluto de incluir un plan de explotación y de actividades de difusión y comunicación
- ✓ En caso de evaluación a ciegas (fase 1), no incluir datos que permitan la identificación de solicitantes en la parte B
- ✓ Límites de páginas (fase única - 45 págs.; fase 1 - 10 págs.) el sistema corta y elimina las págs. que exceden el límite

Anexo B - Elegibilidad

Any legal entity, regardless of its place of establishment, including legal entities from non-associated third countries or international organisations (including international European research organisations) is **eligible to participate (whether it is eligible for funding or not)**, provided that the conditions laid down in the Horizon Europe Regulation have been met, along with any other conditions laid down in the specific call/topic.



Anexo B – Elegibilidad (II)

Beneficiaries and affiliated entities must register in the Participant Register before submitting their application, in order to get a participant identification code (PIC) and be validated by the Central Validation Service (REA Validation) before signing the grant agreement

Otros modos principales de participación

Affiliated entities — Affiliated entities (i.e. entities linked to a beneficiary which participate in the action with similar rights and obligations to the beneficiaries, but which do not sign the grant agreement and therefore do not become beneficiaries themselves) are allowed, if they fulfil the eligibility conditions.

Associated partners — Associated partners (i.e. entities which participate in the action without signing the grant agreement, but without the right to charge costs or claim contributions) are allowed.

Otra información disponible

- Información sobre participación de terceros países
- Existen determinadas restricciones: ej. participación de entidades rusas

Requisito *sine quae non* de elegibilidad

Consortium composition

Unless otherwise provided for in the specific call conditions, legal entities forming a consortium are eligible to participate in actions provided that the consortium includes:

- at least one independent legal entity established in a Member State; and
- at least two other independent legal entities, each established in different Member States or Associated Countries.

Modalidades de financiación más habituales

Research and innovation actions (RIA) — *Activities that aim primarily to establish new knowledge or to explore the feasibility of a new or improved technology, product, process, service or solution.* This may include basic and applied research, technology development and integration, testing, demonstration and validation of a small-scale prototype in a laboratory or simulated environment.

Innovation actions (IA) — *Activities that aim directly to produce plans and arrangements or designs for new, altered or improved products, processes or services.* These activities may include prototyping, testing, demonstrating, piloting, large-scale product validation and market replication.

Coordination and support actions (CSA) — *Activities that contribute to the objectives of Horizon Europe. This excludes R&I activities, except those carried out under the ‘Widening participation and spreading excellence’ component of the programme (part of ‘Widening participation and strengthening the European Research Area’).* Also eligible are bottom-up coordination actions which promote cooperation between legal entities from Member States and Associated Countries to strengthen the European Research Area, and which receive no EU co-funding for research activities.

Technology Readiness Levels (TRL)

Where the specific call conditions require a Technology Readiness Level (TRL), the following definitions apply, unless otherwise specified:

TRL 1 — Basic principles observed

TRL 2 — Technology concept formulated

TRL 3 — Experimental proof of concept

TRL 4 — Technology validated in a lab

TRL 5 — Technology validated in a relevant environment

TRL 6 — Technology demonstrated in a relevant environment

TRL 7 — System prototype demonstration in an operational environment

TRL 8 — System complete and qualified

TRL 9 — Actual system proven in an operational environment

Otros aspectos explicados en el Anexo B

- Ethics
- Security — EU-classified and sensitive information
- Gender equality plans and gender mainstreaming
- Financial support to third parties

Otros anexos

C - Financial and operational capacity and exclusion

D - Award criteria

E - Documents

F - Evaluation (procedure and ranking)

G - Legal and financial set-up of the grant agreements

H - Specific conditions for actions implementing pre-commercial procurement or procurement of innovative solutions

3 criterios de evaluación (RIA e IA)

(máx. 5 puntos por criterios; se admiten medios puntos.

*: Únicos criterios en las convocatorias de dos fases)

Excellence

- **Clarity and pertinence of the project's objectives**, and the **extent to which the proposed work is ambitious and goes beyond the state of the art**.
- **Soundness of the proposed [for the first stage: overall] methodology**, including the underlying concepts, models, assumptions, inter-disciplinary approaches, appropriate consideration of the gender dimension in research and innovation content, and the quality of open science practices, including sharing and management of research outputs and engagement of citizens, civil society and end-users where appropriate.

Impact

- **Credibility of the pathways to achieve the expected outcomes and impacts specified in the work programme**, and the likely scale and significance of the contributions from the project.
- Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities.

Quality and efficiency of the implementation

- Quality and effectiveness of **the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources** overall.
 - **Capacity and role of each participant**, and the extent to which the **consortium as a whole** brings together the necessary expertise.

The threshold for individual criteria will be 3. The overall threshold, applying to the sum of the three individual scores, will be 10.

Importante revisar también



Horizon Europe (HORIZON)

HE Programme Guide

Version 4.1
01 May 2024

Table of contents

1. Introduction	6
2. Terminology explained	7
3. Structure and budget	8
4. What is the Strategic Plan and why is it important?	9
5. Horizon Europe, an impact-driven framework programme	10
6. European Partnerships	11
7. Missions	11
8. International cooperation and association	12
9. Gender equality and inclusiveness	16
10. Social Science and Humanities (SSH)	21
11. Social Innovation	22
12. Ethics and integrity	23
13. Security	28
14. Dissemination and exploitation of research results	31
15. Do No Significant Harm principle.....	39
16. Open science	40
17. Innovation Procurement	56
18. Key Digital Technologies	59

Sesión 2 - 15.05.2024


Agenda

1. Estructura básica de Horizonte Europa
2. Descripción del Programa de Trabajo del Clúster Salud.
3. Análisis de los apartados de un topic
4. Reglas generales de participación
5. ¿Cómo puedo solicitar financiación?

Antes de empezar

- **Analizar repetidas veces el texto del topic.** Cada palabra tiene su sentido. Ojo con la jerga de la CE: p. ej., los should/must/strongly encouraged, and/or, several/some/all
- **Familiarizarse con la terminología:** se incluye lista de definiciones en el formulario guía o “template”: [af_he-ria-ia-stage-1_en.pdf](#).
- **El texto del topic es general** en cuanto a enfoque, pero tiene ciertas acotaciones.
- **La solicitud es una manera de venderse y convencer, no es redactar un ‘paper’,**
- **Redactar para el panel de evaluación,** que es heterogéneo en áreas de ‘expertise’.
- **Tener claro:** ‘Results’: del/en el proyecto; ‘outcomes’: corto/medio plazo; ‘impact’: largo plazo
- Tened en cuenta las notas a pie de páginas. A veces son determinantes.
- **Seguid la estructura del formulario de solicitud** y atended a las explicaciones en el mismo (“el template”)

¿Ser coordinador o ser socio?



Coordinar	Participar como socio
<p>Construcción del consorcio (distribución de tareas): teleconferencias, reuniones físicas. Mayor recurso: TIEMPO, TIEMPO, TIEMPO</p>	<ul style="list-style-type: none"> ● Hacerse visible ● Contactar con un consorcio en formación
<p>Buscar socios potenciales y comprobar elegibilidad (visión europea y global)</p>	<ul style="list-style-type: none"> ● Seguir las indicaciones de la coordinación. ● Reuniones de debate para el diseño de la propuesta
<p>Redacción de un resumen ejecutivo y distribución al consorcio</p>	<p>Compromiso y dedicación: tareas, cumplimiento de plazos, informes, participación en reuniones</p>
<p>Negociación, mano izquierda, golpes de timón, gestión de tiempos y recursos</p>	<p>Participación y flexibilidad</p>
<p>Gestión del proyecto</p>	<p>Actividades comprometidas. Cumplir plazos</p>

La búsqueda de socios / ofrecerse como socios

- Contactos profesionales previos: colaboraciones, congresos, etc.
- Contacto directo según área de experiencia y línea de investigación
- Analizar proyectos europeos ya financiados
- Portal del Participante
 - Oferta de participación en cada topic
 - Búsqueda con palabras clave en

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search>

- Oficina de apoyo IACS o similar
- Contacto con NCPs – brokerage events





Estamos a vuestra disposición para ayudaros a participar en Horizonte Europa.



Elena Portero (eportero.iacs@aragon.es)

Juan Riese (jriesej.iacs@aragon.es)